Andreas Sidiropoulas
Psychiatry · Detroit, MINPI 1871525832
Payments from drug & device makers
Across 2,654 payments — averaging $1047.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1M
- Alkermes, Inc.$554K
- Vanda Pharmaceuticals Inc.$511K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$308K
- E.r. Squibb & Sons, L.L.C.$164K
- Axsome Therapeutics, Inc.$132K
- plus $102K from 12 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Consulting fees$128,7285%
- Speaking & faculty fees$2,105,34576%
- Travel & lodging$498,24918%
- Food & beverage$47,2262%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 1,154 | $1,008,862 |
| Alkermes, Inc. | 451 | $554,382 |
| Vanda Pharmaceuticals Inc. | 406 | $510,787 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 256 | $307,702 |
| E.r. Squibb & Sons, L.L.C. | 113 | $163,868 |
| Axsome Therapeutics, Inc. | 105 | $132,397 |
| Otsuka America Pharmaceutical, Inc. | 105 | $71,172 |
| Sunovion Pharmaceuticals Inc. | 39 | $24,494 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,423 |
| Masimo Corporation | 2 | $1,789 |
| Neurocrine Biosciences, Inc. | 7 | $1,203 |
| Lundbeck LLC | 8 | $175 |
| Johnson & Johnson | 1 | $125 |
| Kyowa Kirin, Inc. | 1 | $122 |
| Titan Pharmaceuticals, Inc. | 1 | $32 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $26 |
| Orexo US, Inc. | 1 | $21 |
| Indivior Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,189,055
- ARISTADA$1,021,661
- VRAYLAR$999,310
- Fanapt$507,667
- CAPLYTA$305,257
- ARISTADA INITIO$241,210
- Auvelity$131,171
- COBENFY$129,108
- REXULTI$55,859
- LATUDA$23,731
- ABILIFY MAINTENA$15,092
- TRINTELLIX$2,423
- INGREZZA$255
- SPRAVATO$125
How this compares
$2,779,595 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 192 | $475,319 |
| AristadaAripiprazole Lauroxil | 58 | $195,114 |
| Abilify MaintenaAripiprazole | 25 | $72,782 |
| VraylarCariprazine Hcl | 40 | $54,988 |
| CaplytaLumateperone Tosylate | 31 | $48,345 |
| Paliperidone ErPaliperidone | 112 | $39,715 |
| VivitrolNaltrexone Microspheres | 19 | $32,678 |
| Risperdal ConstaRisperidone Microspheres | 14 | $27,169 |
| FanaptIloperidone | 14 | $21,869 |
| Clozapine OdtClozapine | 37 | $10,548 |
| Clozapine | 89 | $5,963 |
| Olanzapine OdtOlanzapine | 81 | $5,129 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 95 | $4,127 |
| Haloperidol Decanoate | 32 | $3,770 |
| Chlorpromazine Hcl | 17 | $3,748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $125 | $502,488206 claims |
| Alkermes, Inc.Aristada, Vivitrol | $554,382 | $227,79277 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $71,172 | $72,78225 claims |
| AbbVieVraylar | $1,008,862 | $54,98840 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $307,702 | $48,34531 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $510,787 | $21,86914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,166 psychiatry providers in Michigan.
Other psychiatry in Detroit
- Arash JavanbakhtDetroit$102K
- Matcheri KeshavanDetroit$48K
- Gerald WinderDetroit$30K
- John HeadDetroit$28K
- David HarrisDetroit$11K
- Joel YoungRochester Hills$1.9M
- Welton WashingtonYpsilanti$1.4M
- Rajaprabhakaran RajarethinamAnn Arbor$1.2M
- Eric AchtyesGrand Rapids$705K
- Manzar RajputMonroe$612K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.